References in periodicals archive ?
Lenvima (lenvatinib, Eisai)- Opdivo (nivolumab, Bristol-Myers Squibb)- Keytruda (pembrolizumab, Merck)- Cometriq (cabozantinib, Exelixis)- Tivantinib (ARQ197, ArQule/Daiichi Sankyo)- IMA901 (Immatics Biotechnologies/Roche)- Atezolizumab (MPDL3280A/Roche).
Discussions appear for 21 drug candidates in the pipeline, including these agents: -- Lenvima (lenvatinib, Eisai) -- Opdivo (nivolumab, Bristol-Myers Squibb) -- Keytruda (pembrolizumab, Merck) -- Cometriq (cabozantinib, Exelixis) -- Tivantinib (ARQ197, ArQule/Daiichi Sankyo) -- IMA901 (Immatics Biotechnologies/Roche) -- Atezolizumab (MPDL3280A/Roche).
Sobi is responsible for the commercialization and distribution of Cometriq (cabozantinib) for progressive, unresectable, locally advanced or metastatic medullary thyroid cancer (MTC) in the European Union (EU), Switzerland, Norway, Russia, and Turkey.
Should I start him on Cometriq at a cost of PS80,000 a year or just make sure he's as comfortable as possible?
and Exelixis for its prostate cancer drug Cometriq.
Announced in November 2012 that the European Medicines Agency (EMA) completed validation and accepted for review Exelixis' marketing authorization application (MAA) for COMETRIQ for the proposed indication of treatment of progressive, unresectable, locally advanced or metastatic MTC.
No other indication is covered by this agreement, and Exelixis maintains full commercial rights for COMETRIQ in MTC outside the covered territory and for all other indications on a global basis.
The Company is focusing on resources, development and commercialization of COMETRIQ (cabozantinib) for the treatment of progressive, metastatic medullary thyroid cancer (MTC) in the United States.
Prior to Cleave Biosciences, he held positions of increasing responsibility at Exelixis, making major contributions to the preclinical characterization and IND/NDA filings for COMETRIQ (cabozantanib).
Food and Drug Administration (FDA) approved COMETRIQ on November 29, 2012.
COMETRIQ is an inhibitor of multiple receptor tyrosine kinases involved in both normal cellular function and pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, and maintenance of the tumor microenvironment.
Exelixis) announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion of the Marketing Authorization Application (MAA) for COMETRIQ (cabozantinib) for the treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma (MTC).